JP2007510667A5 - - Google Patents

Download PDF

Info

Publication number
JP2007510667A5
JP2007510667A5 JP2006538522A JP2006538522A JP2007510667A5 JP 2007510667 A5 JP2007510667 A5 JP 2007510667A5 JP 2006538522 A JP2006538522 A JP 2006538522A JP 2006538522 A JP2006538522 A JP 2006538522A JP 2007510667 A5 JP2007510667 A5 JP 2007510667A5
Authority
JP
Japan
Prior art keywords
inhibitor
solvate
iii
salt
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006538522A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007510667A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/037027 external-priority patent/WO2005046678A1/en
Publication of JP2007510667A publication Critical patent/JP2007510667A/ja
Publication of JP2007510667A5 publication Critical patent/JP2007510667A5/ja
Pending legal-status Critical Current

Links

JP2006538522A 2003-11-07 2004-11-05 癌の治療法 Pending JP2007510667A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51821203P 2003-11-07 2003-11-07
PCT/US2004/037027 WO2005046678A1 (en) 2003-11-07 2004-11-05 Cancer treatment method

Publications (2)

Publication Number Publication Date
JP2007510667A JP2007510667A (ja) 2007-04-26
JP2007510667A5 true JP2007510667A5 (enExample) 2007-12-27

Family

ID=34590233

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006538522A Pending JP2007510667A (ja) 2003-11-07 2004-11-05 癌の治療法

Country Status (4)

Country Link
US (1) US20070161665A1 (enExample)
EP (1) EP1682123A1 (enExample)
JP (1) JP2007510667A (enExample)
WO (1) WO2005046678A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200523262A (en) * 2003-07-29 2005-07-16 Smithkline Beecham Corp Inhibitors of AKT activity
EP1809282B1 (en) 2004-10-18 2013-01-09 Amgen, Inc Thiadiazole compounds and methods of use
US7625890B2 (en) 2005-11-10 2009-12-01 Smithkline Beecham Corp. Substituted imidazo[4,5-c]pyridine compounds as Akt inhibitors
CN101003514A (zh) 2006-01-20 2007-07-25 上海艾力斯医药科技有限公司 喹唑啉衍生物、其制备方法及用途
KR101533461B1 (ko) * 2006-04-26 2015-07-02 에프. 호프만-라 로슈 아게 Ｐｉ３ｋ저해제로 유용한 티에노［3,2-ｄ］피리미딘 유도체
SI2024372T1 (sl) * 2006-04-26 2010-10-29 Hoffmann La Roche Tieno(3,2-d)pirimidinski derivat, uporaben kot inhibitor PI3K
EP2054063A4 (en) * 2006-08-22 2010-10-27 Concert Pharmaceuticals Inc 4-AMINOCHINAZOLINE DERIVATIVES AND METHOD FOR THEIR USE
US20110053964A1 (en) * 2006-08-22 2011-03-03 Roger Tung 4-aminoquinazoline derivatives and methods of use thereof
JPWO2008032876A1 (ja) * 2006-09-15 2010-01-28 学校法人東海大学 Ｅｒ陰性およびｈｅｒ２陰性である乳癌の予防または治療剤およびそのスクリーニング方法
WO2008063853A2 (en) * 2006-11-21 2008-05-29 Smithkline Beecham (Cork) Limited Cancer treatment method
WO2009011880A2 (en) 2007-07-17 2009-01-22 Amgen Inc. Heterocyclic modulators of pkb
WO2009011871A2 (en) 2007-07-17 2009-01-22 Amgen Inc. Thiadiazole modulators of pkb
US8252805B2 (en) 2008-05-07 2012-08-28 Teva Pharmaceutical Industries Ltd. Forms of lapatinib ditosylate and processes for preparation thereof
JP2011521214A (ja) * 2008-05-16 2011-07-21 セルゾーム アーゲー Ｐａｒｐ相互作用分子の同定およびｐａｒｐタンパク質の精製のための方法
US20100197915A1 (en) * 2008-08-06 2010-08-05 Leonid Metsger Lapatinib intermediates
WO2011002523A1 (en) 2009-07-02 2011-01-06 Kanionusa Inc. Phosphorus containing quinazoline compounds and methods of use
BRPI1107182B1 (pt) * 2011-12-29 2022-03-08 Fundação De Amparo À Pesquisa Do Estado De Minas Gerais - Fapemig Composições farmacêuticas contendo ang-(1-7) ou outro agonista do receptor mas em combinação com inibidores de pi3k/akt para tratamento terapêutico anticâncer
CZ2012712A3 (cs) 2012-10-17 2014-04-30 Zentiva, K.S. Nový způsob výroby klíčového intermediátu výroby lapatinibu
WO2014170910A1 (en) 2013-04-04 2014-10-23 Natco Pharma Limited Process for the preparation of lapatinib
CN104109152A (zh) * 2013-04-19 2014-10-22 上海医药工业研究院 一种制备拉帕替尼的方法
WO2015100459A2 (en) 2013-12-27 2015-07-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
CN112888440A (zh) 2018-10-16 2021-06-01 豪夫迈·罗氏有限公司 Akt抑制剂在眼科中的用途
WO2024155945A1 (en) * 2023-01-20 2024-07-25 Dermbiont, Inc. Compositions and formulations for the prevention, treatment, and improvement of skin diseases, conditions, and disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9800569D0 (en) * 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
JP2001247477A (ja) * 2000-03-03 2001-09-11 Teikoku Hormone Mfg Co Ltd 抗腫瘍剤
DE60203260T2 (de) * 2001-01-16 2006-02-02 Glaxo Group Ltd., Greenford Pharmazeutische kombination, die ein 4-chinazolinamin und paclitaxel, carboplatin oder vinorelbin enthält, zur behandlung von krebs

Similar Documents

Publication Publication Date Title
JP2007510667A5 (enExample)
LTPA2017011I1 (lt) Antikūnas prieš PDGFR-alfa, skirtas naudoti auglių gydymui
JP2005518413A5 (enExample)
PT1506781E (pt) Composicao para tratamento vaginal
EP2210092A4 (en) SEMAPHORINE COMPREHENSIVE COMPOSITIONS FOR THE TREATMENT OF DISEASES RELATED TO ANGIOGENESIS AND SELECTION PROCEDURES THEREFOR
JP2004504382A5 (enExample)
JP2009545527A5 (enExample)
JP2009502793A5 (enExample)
JP2009502743A5 (enExample)
IL182010A0 (en) Heteroaryl compounds for use as betamimetics in the treatment of respiratory diseases
CL2007003444A1 (es) Compuestos derivados de pirrolo[3,2-c]piridina; composicion farmaceutica; y uso en el tratamiento de un trastorno hiperproliferativo o una enfermedad inflamatoria.
EE05394B1 (et) Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis
PT1701944E (pt) 4¿arilpiramidinas 2¿(amino substituídas)e compostos relacionados úteis no tratamento de doenças inflamatórias
EP2207892A4 (en) METHOD FOR SELECTION OF ACTIVE AGENTS FOR CANCER TREATMENT
JP2006514116A5 (enExample)
RU2008150250A (ru) Способ лечения рака
JP2008513510A5 (enExample)
EP1970063A4 (en) THERAPEUTIC AGENT AGAINST DIABETES
FR2864552B1 (fr) Traitement de surface par hydroxysulfate
JP2004502684A5 (enExample)
JP2008524329A5 (enExample)
NO20070892L (no) Sammensetninger av N-glykolylneuraminsyre og anvendelse derav ved behandling av forkjølelse.
JP2008517059A5 (enExample)
SI1545710T1 (sl) Uporaba N-(3-metoksi-5-metilpirazin-2-il)-2-(4-(1,3,4-oksadiazol-2-il)fenil) piridin-3-sulfonamida v zdravljenju raka
BRPI0821116A2 (pt) Composto, composição farmacêutica que o contem, uso deste e método para tratar qualquer mamífero afetado por câncer